TrianglePUBLICATIONS · 35486638
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Clin Cancer Res
- Publication date
- 2022 Jul 1
- First author
- Subbiah V
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Subbiah V
- type
- Author
- name
- Braña I
- type
- Author
- name
- Longhi A
- type
- Author
- name
- Boni V
- type
- Author
- name
- Delord JP
- type
- Author
- name
- Awada A
- type
- Author
- name
- Boudou-Rouquette P
- type
- Author
- name
- Sarantopoulos J
- type
- Author
- name
- Shapiro GI
- type
- Author
- name
- Elias A
- type
- Author
- name
- Ratan R
- type
- Author
- name
- Fernandez C
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Subbiah V
- type
- Author
- name
- Braña I
- type
- Author
- name
- Longhi A
- type
- Author
- name
- Boni V
- type
- Author
- name
- Delord JP
- type
- Author
- name
- Awada A
- type
- Author
- name
- Boudou-Rouquette P
- type
- Author
- name
- Sarantopoulos J
- type
- Author
- name
- Shapiro GI
- type
- Author
- name
- Elias A
- type
- Author
- name
- Ratan R
- type
- Author
- name
- Fernandez C
- type
- Author
- bibliography ids
- nci-bib-ed8bb63b09071780d0dccded
- book metadata
- content sha256
- bf9da539bd0728ff953a515ebe7415c96bb345f1f981cde408d6a38b197e415c
- document type
- citation
- dois
- 10.1158/1078-0432.CCR-22-0696
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:35486638
- immutable id
- pubmed:35486638@bf9da539bd0728ff953a515ebe7415c96bb345f1f981cde408d6a38b197e415c
- journal
- abbreviation
- Clin Cancer Res
- issn electronic
- 1557-3265
- issn print
- 1078-0432
- issue
- 13
- name
- Clinical cancer research : an official journal of the American Association for Cancer Research
- nlm unique id
- 9502500
- pages
- 2762-2770
- volume
- 28
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 35486638
- provenance
- batch id
- 9d150d55960e0c12aada
- provider
- NCBI PubMed ESummary
- record sha256
- 22ae0ac28ec47c34ac3d59eb01747e60c1ec66fde427d554af471155fee05c53
- response sha256
- 2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
- retrieved at
- 2026-09-09T23:48:09.820498+00:00
- publication date
- display
- 2022 Jul 1
- precision
- day
- year
- 2022
- publication types
- Clinical Trial, Phase II
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
Preserved source evidence · Not medical advice